Is ClearPoint Neuro going out of business?

ClearPoint Neuro, Inc. (CLPT) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

ClearPoint Neuro, Inc. (CLPT) scores 26 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: ROIC: -52.42%

Five questions, kept separate

Survival - Funding dependent

12-17 mo of estimated runway from 2026-06-30, based on $29.4M of cash and short-term investments against $24.4M of annual burn. Debt pressure is the other decisive risk.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

-5.1% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• ROIC: -52.42%
• FCF margin: -66.12%
• Debt / Equity: 5.93x
• Revenue CAGR (3Y): 21.62%
• R&D intensity: 34.10%
• Return on Assets: -29.44%
• Debt Maturity Runway: 100% long-term (Long-term focused)
• Revenue growth YoY: 18.07% (YoY)
• Cash Burn Deceleration: -105.04% QoQ improvement (Worsening)
• Revenue Quality: Quality concerns (DSO +37d, Rev +18%)
• Price / Sales: 11.4x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-03.

Price as of 2026-09-07.